Outcomes In Patients With Advanced Non-Small Cell Lung Cancer (Ansclc) And High Pd-L1 Expression Treated With Immune Checkpoint Inhibitor Monotherapy: An Fda-Pooled Analysis.

Sujay Yogesh Shah,Jonathon Joseph Vallejo,Yutao Gong,Thomas D. Brown,Chenan Zhang,Jonathan Hirsch,Shenghui Tang,Gideon Michael Blumenthal,Harpreet Singh,Paul Gustav Kluetz,Marc Robert Theoret,Julia A. Beaver,Richard Pazdur

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 2|浏览12

暂无评分

摘要

9606Background: Higher PD-L1 score ≥ 50% predicts for greater benefit to immune checkpoint inhibitor (ICI) therapy in first line (1L) treatment of aNSCLC. It has recently been reported that PD-L1 s...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要